Brokerages forecast that Catalent (NYSE:CTLT) will report $609.36 million in sales for the current quarter, Zacks reports. Six analysts have issued estimates for Catalent’s earnings, with estimates ranging from $599.58 million to $622.50 million. Catalent reported sales of $532.60 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.4%. The business is scheduled to report its next earnings report on Thursday, May 3rd.
On average, analysts expect that Catalent will report full year sales of $609.36 million for the current year, with estimates ranging from $2.44 billion to $2.47 billion. For the next year, analysts anticipate that the company will post sales of $2.64 billion per share, with estimates ranging from $2.53 billion to $2.76 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Catalent.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.10. The business had revenue of $606.30 million for the quarter, compared to analysts’ expectations of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The business’s quarterly revenue was up 25.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.27 earnings per share.
Shares of Catalent stock opened at $41.56 on Thursday. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22. Catalent has a one year low of $27.48 and a one year high of $47.87. The firm has a market cap of $5,439.40, a P/E ratio of 72.91, a P/E/G ratio of 2.34 and a beta of 1.54.
In other Catalent news, SVP William Downie sold 9,082 shares of the stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $41.80, for a total value of $379,627.60. Following the transaction, the senior vice president now directly owns 46,986 shares in the company, valued at $1,964,014.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.70% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Xact Kapitalforvaltning AB purchased a new position in Catalent in the fourth quarter valued at approximately $513,000. Envestnet Asset Management Inc. increased its stake in Catalent by 5.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 29,439 shares of the company’s stock valued at $1,209,000 after purchasing an additional 1,430 shares during the last quarter. We Are One Seven LLC purchased a new position in Catalent in the fourth quarter valued at approximately $343,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new position in Catalent in the fourth quarter valued at approximately $242,000. Finally, Segall Bryant & Hamill LLC purchased a new position in Catalent in the fourth quarter valued at approximately $9,035,000. Institutional investors own 99.89% of the company’s stock.
WARNING: “Catalent (CTLT) Expected to Post Quarterly Sales of $609.36 Million” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://stocknewstimes.com/2018/03/22/catalent-ctlt-expected-to-post-quarterly-sales-of-609-36-million.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.